<DOC>
	<DOC>NCT01063023</DOC>
	<brief_summary>To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects</brief_summary>
	<brief_title>Drug Interaction Oral Contraceptive Pill (OCP)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>Healthy Females, 1840 years, BMI 18 32kg/mÂ². Must use an acceptable method of contraception to avoid pregnancy throughout the study and 8 weeks after last dose of study drug Abnormal pap smear within 1 year prior to day 1 Any significant or chronic uncontrolled medical illness</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>